<p>Harvest Portfolios Group Inc. 在最近向證券交易委員會提交的 13F 文件中表示，在第四季度將其在雅培（NYSE:ABT - 免費報告）股票中的持股比例提高了 5.4%。該機構投資者在此期間購買了額外的 24,559 股後，持有 481,458 股該醫療產品製造商的股票。Harvest Portfolios Group Inc. 在雅培的持股在最近的報告期末價值為 60,322,000 美元。</p>
<ul>
<li>雅培發出健康趨勢跟隨信號：反彈即將來臨？</li>
</ul>
<p>其他一些機構投資者和對沖基金最近也增加或減少了在該股票中的持股。Fideuram Intesa Sanpaolo Private Banking S.P.A. 在第四季度購買了價值 2,054,000 美元的雅培新股份。PNC Financial Services Group Inc. 在第四季度將其在雅培的持股增加了 1.8%。PNC Financial Services Group Inc. 現在持有 4,663,821 股該醫療產品製造商的股票，價值 584,330,000 美元，此前在此期間購買了額外的 83,377 股。Saranac Partners Ltd 在第四季度將其在雅培的持股增加了 5.5%。Saranac Partners Ltd 現在持有 4,335 股該醫療產品製造商的股票，價值 544,000 美元，此前在上個季度購買了額外的 225 股。Larson Financial Group LLC 在第四季度將其在雅培的持股增加了 5.2%。Larson Financial Group LLC 現在持有 16,866 股該醫療產品製造商的股票，價值 2,113,000 美元，此前在上個季度購買了額外的 835 股。最後，Handelsbanken Fonder AB 在第四季度將其在雅培的持股提高了 11.4%。Handelsbanken Fonder AB 現在持有 1,220,202 股該醫療產品製造商的股票，價值 152,879,000 美元，此前在此期間獲得了額外的 124,733 股。機構投資者持有該公司 75.18% 的股票。</p>
<p>獲取 <strong>雅培</strong> 的提醒：</p>
<h2>雅培股票上漲 1.0%</h2>
<p>NYSE:ABT 週三開盤價為 88.81 美元。雅培的 1 年低點為 81.97 美元，1 年高點為 139.06 美元。該公司的 50 日移動平均線為 98.14 美元，200 日移動平均線為 112.73 美元。該公司的市值為 1547 億美元，市盈率為 24.88，市盈率增長比率為 1.47，貝塔值為 0.65。該公司的債務與股本比率為 0.56，流動比率為 1.39，速動比率為 1.01。</p>
<ul>
<li>雅培股票崩盤：反彈可能即將到來</li>
</ul>
<p>雅培（NYSE:ABT - 獲取免費報告）最近於 4 月 16 日星期四發佈了季度財報。該醫療產品製造商報告本季度每股收益為 1.15 美元，超出分析師一致預期的 1.14 美元，超出 0.01 美元。該公司本季度的收入為 111.6 億美元，而分析師預期為 109.9 億美元。雅培的淨利潤率為 13.90%，股本回報率為 17.62%。該公司本季度的收入較去年同期增長了 7.8%。在去年同期，該公司每股收益為 1.09 美元。雅培已將其 2026 財年的指導目標設定為每股收益 5.380-5.580 美元，2026 年第二季度的指導目標為每股收益 1.250-1.310 美元。整體來看，研究分析師預計雅培在當前財年將發佈每股收益 5.48 美元。</p>
<h2>雅培分紅公告</h2>
<p>該公司最近還宣佈了季度分紅，已於 5 月 15 日星期五支付。4 月 15 日星期三的股東獲得每股 0.63 美元的分紅。這代表着每年 2.52 美元的分紅和 2.8% 的收益率。該分紅的除息日為 4 月 15 日星期三。雅培的分紅支付比率（DPR）為 70.59%。</p>
<h2>雅培的內部買賣</h2>
<ul>
<li>一家分紅王正在打折出售：雅培實驗室是醫療保健的便宜貨嗎？</li>
</ul>
<p>在其他雅培新聞中，副總裁 John A. Jr. Mccoy 於 3 月 2 日星期一出售了 585 股該股票。該股票以平均價格 115.58 美元出售，總交易額為 67,614.30 美元。出售後，該副總裁持有 24,628 股公司股票，價值約 2,846,504.24 美元。此交易代表其持股減少了 2.32%。該出售在向證券交易委員會的法律文件中披露，可以通過此超鏈接訪問。此外，首席財務官 Philip P. Boudreau 於 4 月 23 日星期四購買了 2,200 股該公司的股票。該股票以每股 91.50 美元的平均成本購買，總交易額為 201,300.00 美元。交易後，首席財務官持有 2,200 股公司股票，價值約 201,300 美元。該交易使其持股增加了 ∞。該購買的 SEC 文件提供了更多信息。在過去三個月中，內部人士已出售價值 353,097 美元的 3,055 股公司股票。當前 0.46% 的股票由公司內部人士持有。</p>
<h2>華爾街分析師預測增長</h2>
<p>幾位股票分析師最近對雅培的股票發表了評論。瑞銀集團在 4 月 20 日的研究報告中將雅培的目標價從 158.00 美元下調至 135.00 美元，並對該股票給予了 “買入” 評級。大和證券集團在 4 月 22 日的報告中將雅培的股票評級從 “跑贏大盤” 下調至 “中性”，並設定了 92.00 美元的目標價。桑福德·伯恩斯坦在 4 月 17 日的報告中將雅培的目標價從 125.00 美元下調至 110.00 美元，並對該股票給予了 “跑贏大盤” 評級。傑富瑞金融集團在 4 月 17 日的報告中將雅培的股票目標價從 145.00 美元下調至 135.00 美元，並對該股票給予了 “買入” 評級。最後，雷蒙德·詹姆斯金融在 4 月 17 日的研究報告中將雅培的目標價從 130.00 美元下調至 115.00 美元，並對該股票給予了 “跑贏大盤” 評級。兩位投資分析師對該股票給予了強烈買入評級，十九位分析師給予了買入評級，五位分析師給予了持有評級。根據 MarketBeat 的數據，該股票目前的共識評級為 “適度買入”，平均目標價為 119.43 美元。</p>
<p><strong>閲讀我們對雅培的最新股票分析</strong></p>
<h2>關於雅培</h2>
<p>（免費報告）</p>
<p>雅培是一家全球醫療保健公司，總部位於伊利諾伊州的雅培公園，開發、製造和銷售廣泛的醫療產品和服務。雅培成立於 1888 年，通過多個業務領域運營，專注於診斷、醫療設備、營養品和成熟藥品。該公司向醫院、診所、實驗室、零售商和直接面向消費者的渠道提供旨在診斷、治療和管理各種健康狀況的產品。</p>
<p>在診斷方面，雅培提供實驗室和現場檢測平台及用於檢測傳染病、慢性病和生物標誌物的檢測方法；其 Alinity 系列儀器和快速檢測解決方案就是這一能力的例子。</p>
<h2>精選文章</h2>
<ul>
<li>我們更看好的五隻股票超過雅培</li>
<li>HIVE 利用電力進行人工智能轉型</li>
<li>深入探討 NVIDIA 最新的投資組合動態</li>
<li>布雷迪公司推出大規模人工智能驅動的突破</li>
<li>為什麼家得寶的拋售可能成為一個巨大機會</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUFCVA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUFCVA"/></p>
<p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。如對本故事有任何問題或意見，請發送電子郵件至 contact@marketbeat.com.</em></p>
<h2>你現在應該投資 1000 美元在雅培嗎？</h2>
<p>在考慮雅培之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師正在悄悄建議客户現在購買的股票，以便在更廣泛的市場注意到之前……而雅培並不在名單上。</p>
<p>雖然雅培目前在分析師中獲得了適度買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

雅培

美國醫藥設備 ETF - iShares

標普全球醫療股指數 ETF - iShares

標普健康醫療設備 ETF - SPDR

醫療業 ETF - SPDR

醫療業 ETF - Vanguard

<p>Harvest Portfolios Group Inc. 在第四季度將其在雅培（NYSE:ABT）的股份增加了 5.4%，目前持有 481,458 股，價值 6032 萬美元。其他機構投資者也調整了他們的持股。雅培的股票開盤價為 88.81 美元，市值為 1547 億美元。該公司報告第一季度每股收益為 1.15 美元，超出預期，並宣佈季度股息為每股 0.63 美元</p>

<p>Harvest Portfolios Group Inc. boosted its stake in shares of Abbott Laboratories (NYSE:ABT - Free Report) by 5.4% in the fourth quarter, according to the company in its most recent 13F filing with the Securities &amp; Exchange Commission. The institutional investor owned 481,458 shares of the healthcare product maker's stock after buying an additional 24,559 shares during the period. Harvest Portfolios Group Inc.'s holdings in Abbott Laboratories were worth $60,322,000 at the end of the most recent reporting period.</p>
<div class="lb-trans"><p>Harvest Portfolios Group Inc. 在最近向證券交易委員會提交的 13F 文件中表示，在第四季度將其在雅培（NYSE:ABT - 免費報告）股票中的持股比例提高了 5.4%。該機構投資者在此期間購買了額外的 24,559 股後，持有 481,458 股該醫療產品製造商的股票。Harvest Portfolios Group Inc. 在雅培的持股在最近的報告期末價值為 60,322,000 美元。</p>
</div><ul>
<li>AbbVie Fires Healthy Trend-Following Signal: Is a Rebound Ahead?</li>
</ul>
<div class="lb-trans"><ul>
<li>雅培發出健康趨勢跟隨信號：反彈即將來臨？</li>
</ul>
</div><p>A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. Fideuram Intesa Sanpaolo Private Banking S.P.A. purchased a new stake in shares of Abbott Laboratories during the fourth quarter valued at $2,054,000. PNC Financial Services Group Inc. grew its stake in shares of Abbott Laboratories by 1.8% during the 4th quarter. PNC Financial Services Group Inc. now owns 4,663,821 shares of the healthcare product maker's stock valued at $584,330,000 after purchasing an additional 83,377 shares during the period. Saranac Partners Ltd increased its stake in shares of Abbott Laboratories by 5.5% in the 4th quarter. Saranac Partners Ltd now owns 4,335 shares of the healthcare product maker's stock worth $544,000 after purchasing an additional 225 shares in the last quarter. Larson Financial Group LLC increased its stake in shares of Abbott Laboratories by 5.2% in the 4th quarter. Larson Financial Group LLC now owns 16,866 shares of the healthcare product maker's stock worth $2,113,000 after purchasing an additional 835 shares in the last quarter. Finally, Handelsbanken Fonder AB raised its stake in Abbott Laboratories by 11.4% during the 4th quarter. Handelsbanken Fonder AB now owns 1,220,202 shares of the healthcare product maker's stock worth $152,879,000 after acquiring an additional 124,733 shares during the period. Institutional investors own 75.18% of the company's stock.</p>
<div class="lb-trans"><p>其他一些機構投資者和對沖基金最近也增加或減少了在該股票中的持股。Fideuram Intesa Sanpaolo Private Banking S.P.A. 在第四季度購買了價值 2,054,000 美元的雅培新股份。PNC Financial Services Group Inc. 在第四季度將其在雅培的持股增加了 1.8%。PNC Financial Services Group Inc. 現在持有 4,663,821 股該醫療產品製造商的股票，價值 584,330,000 美元，此前在此期間購買了額外的 83,377 股。Saranac Partners Ltd 在第四季度將其在雅培的持股增加了 5.5%。Saranac Partners Ltd 現在持有 4,335 股該醫療產品製造商的股票，價值 544,000 美元，此前在上個季度購買了額外的 225 股。Larson Financial Group LLC 在第四季度將其在雅培的持股增加了 5.2%。Larson Financial Group LLC 現在持有 16,866 股該醫療產品製造商的股票，價值 2,113,000 美元，此前在上個季度購買了額外的 835 股。最後，Handelsbanken Fonder AB 在第四季度將其在雅培的持股提高了 11.4%。Handelsbanken Fonder AB 現在持有 1,220,202 股該醫療產品製造商的股票，價值 152,879,000 美元，此前在此期間獲得了額外的 124,733 股。機構投資者持有該公司 75.18% 的股票。</p>
</div><p>Get <strong>Abbott Laboratories</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>雅培</strong> 的提醒：</p>
</div><h2>Abbott Laboratories Stock Up 1.0%</h2>
<div class="lb-trans"><h2>雅培股票上漲 1.0%</h2>
</div><p>NYSE:ABT opened at $88.81 on Wednesday. Abbott Laboratories has a 1-year low of $81.97 and a 1-year high of $139.06. The company has a 50-day moving average of $98.14 and a 200 day moving average of $112.73. The firm has a market cap of $154.70 billion, a PE ratio of 24.88, a price-to-earnings-growth ratio of 1.47 and a beta of 0.65. The company has a debt-to-equity ratio of 0.56, a current ratio of 1.39 and a quick ratio of 1.01.</p>
<div class="lb-trans"><p>NYSE:ABT 週三開盤價為 88.81 美元。雅培的 1 年低點為 81.97 美元，1 年高點為 139.06 美元。該公司的 50 日移動平均線為 98.14 美元，200 日移動平均線為 112.73 美元。該公司的市值為 1547 億美元，市盈率為 24.88，市盈率增長比率為 1.47，貝塔值為 0.65。該公司的債務與股本比率為 0.56，流動比率為 1.39，速動比率為 1.01。</p>
</div><ul>
<li>Abbott Stock Crash: Rebound Could Be Coming Fast</li>
</ul>
<div class="lb-trans"><ul>
<li>雅培股票崩盤：反彈可能即將到來</li>
</ul>
</div><p>Abbott Laboratories (NYSE:ABT - Get Free Report) last released its quarterly earnings data on Thursday, April 16th. The healthcare product maker reported $1.15 earnings per share for the quarter, topping analysts' consensus estimates of $1.14 by $0.01. The company had revenue of $11.16 billion during the quarter, compared to analyst estimates of $10.99 billion. Abbott Laboratories had a net margin of 13.90% and a return on equity of 17.62%. The firm's revenue for the quarter was up 7.8% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.09 earnings per share. Abbott Laboratories has set its FY 2026 guidance at 5.380-5.580 EPS and its Q2 2026 guidance at 1.250-1.310 EPS. As a group, research analysts anticipate that Abbott Laboratories will post 5.48 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>雅培（NYSE:ABT - 獲取免費報告）最近於 4 月 16 日星期四發佈了季度財報。該醫療產品製造商報告本季度每股收益為 1.15 美元，超出分析師一致預期的 1.14 美元，超出 0.01 美元。該公司本季度的收入為 111.6 億美元，而分析師預期為 109.9 億美元。雅培的淨利潤率為 13.90%，股本回報率為 17.62%。該公司本季度的收入較去年同期增長了 7.8%。在去年同期，該公司每股收益為 1.09 美元。雅培已將其 2026 財年的指導目標設定為每股收益 5.380-5.580 美元，2026 年第二季度的指導目標為每股收益 1.250-1.310 美元。整體來看，研究分析師預計雅培在當前財年將發佈每股收益 5.48 美元。</p>
</div><h2>Abbott Laboratories Dividend Announcement</h2>
<div class="lb-trans"><h2>雅培分紅公告</h2>
</div><p>The business also recently announced a quarterly dividend, which was paid on Friday, May 15th. Shareholders of record on Wednesday, April 15th were given a dividend of $0.63 per share. This represents a $2.52 annualized dividend and a yield of 2.8%. The ex-dividend date of this dividend was Wednesday, April 15th. Abbott Laboratories's dividend payout ratio (DPR) is 70.59%.</p>
<div class="lb-trans"><p>該公司最近還宣佈了季度分紅，已於 5 月 15 日星期五支付。4 月 15 日星期三的股東獲得每股 0.63 美元的分紅。這代表着每年 2.52 美元的分紅和 2.8% 的收益率。該分紅的除息日為 4 月 15 日星期三。雅培的分紅支付比率（DPR）為 70.59%。</p>
</div><h2>Insider Buying and Selling at Abbott Laboratories</h2>
<div class="lb-trans"><h2>雅培的內部買賣</h2>
</div><ul>
<li>A Dividend King on Sale: Is Abbott Labs a Healthcare Bargain?</li>
</ul>
<div class="lb-trans"><ul>
<li>一家分紅王正在打折出售：雅培實驗室是醫療保健的便宜貨嗎？</li>
</ul>
</div><p>In other Abbott Laboratories news, VP John A. Jr. Mccoy sold 585 shares of the stock in a transaction on Monday, March 2nd. The stock was sold at an average price of $115.58, for a total transaction of $67,614.30. Following the sale, the vice president owned 24,628 shares of the company's stock, valued at approximately $2,846,504.24. This trade represents a 2.32% decrease in their position. The sale was disclosed in a legal filing with the Securities &amp; Exchange Commission, which can be accessed through this hyperlink. Also, CFO Philip P. Boudreau acquired 2,200 shares of the business's stock in a transaction dated Thursday, April 23rd. The stock was purchased at an average cost of $91.50 per share, for a total transaction of $201,300.00. Following the transaction, the chief financial officer owned 2,200 shares in the company, valued at approximately $201,300. The trade was a ∞ increase in their ownership of the stock. The SEC filing for this purchase provides additional information. In the last three months, insiders have sold 3,055 shares of company stock worth $353,097. 0.46% of the stock is currently owned by company insiders.</p>
<div class="lb-trans"><p>在其他雅培新聞中，副總裁 John A. Jr. Mccoy 於 3 月 2 日星期一出售了 585 股該股票。該股票以平均價格 115.58 美元出售，總交易額為 67,614.30 美元。出售後，該副總裁持有 24,628 股公司股票，價值約 2,846,504.24 美元。此交易代表其持股減少了 2.32%。該出售在向證券交易委員會的法律文件中披露，可以通過此超鏈接訪問。此外，首席財務官 Philip P. Boudreau 於 4 月 23 日星期四購買了 2,200 股該公司的股票。該股票以每股 91.50 美元的平均成本購買，總交易額為 201,300.00 美元。交易後，首席財務官持有 2,200 股公司股票，價值約 201,300 美元。該交易使其持股增加了 ∞。該購買的 SEC 文件提供了更多信息。在過去三個月中，內部人士已出售價值 353,097 美元的 3,055 股公司股票。當前 0.46% 的股票由公司內部人士持有。</p>
</div><h2>Wall Street Analysts Forecast Growth</h2>
<div class="lb-trans"><h2>華爾街分析師預測增長</h2>
</div><p>Several equities analysts have recently commented on ABT shares. UBS Group lowered their price objective on Abbott Laboratories from $158.00 to $135.00 and set a &#34;buy&#34; rating on the stock in a research report on Monday, April 20th. Daiwa Securities Group downgraded shares of Abbott Laboratories from an &#34;outperform&#34; rating to a &#34;neutral&#34; rating and set a $92.00 target price on the stock. in a report on Wednesday, April 22nd. Sanford C. Bernstein decreased their price target on Abbott Laboratories from $125.00 to $110.00 and set an &#34;outperform&#34; rating on the stock in a report on Friday, April 17th. Jefferies Financial Group cut their price target on shares of Abbott Laboratories from $145.00 to $135.00 and set a &#34;buy&#34; rating on the stock in a report on Friday, April 17th. Finally, Raymond James Financial reduced their target price on Abbott Laboratories from $130.00 to $115.00 and set an &#34;outperform&#34; rating on the stock in a research note on Friday, April 17th. Two investment analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and five have assigned a Hold rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of &#34;Moderate Buy&#34; and an average price target of $119.43.</p>
<div class="lb-trans"><p>幾位股票分析師最近對雅培的股票發表了評論。瑞銀集團在 4 月 20 日的研究報告中將雅培的目標價從 158.00 美元下調至 135.00 美元，並對該股票給予了 “買入” 評級。大和證券集團在 4 月 22 日的報告中將雅培的股票評級從 “跑贏大盤” 下調至 “中性”，並設定了 92.00 美元的目標價。桑福德·伯恩斯坦在 4 月 17 日的報告中將雅培的目標價從 125.00 美元下調至 110.00 美元，並對該股票給予了 “跑贏大盤” 評級。傑富瑞金融集團在 4 月 17 日的報告中將雅培的股票目標價從 145.00 美元下調至 135.00 美元，並對該股票給予了 “買入” 評級。最後，雷蒙德·詹姆斯金融在 4 月 17 日的研究報告中將雅培的目標價從 130.00 美元下調至 115.00 美元，並對該股票給予了 “跑贏大盤” 評級。兩位投資分析師對該股票給予了強烈買入評級，十九位分析師給予了買入評級，五位分析師給予了持有評級。根據 MarketBeat 的數據，該股票目前的共識評級為 “適度買入”，平均目標價為 119.43 美元。</p>
</div><p><strong>Read Our Latest Stock Analysis on Abbott Laboratories</strong></p>
<div class="lb-trans"><p><strong>閲讀我們對雅培的最新股票分析</strong></p>
</div><h2>About Abbott Laboratories</h2>
<div class="lb-trans"><h2>關於雅培</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免費報告）</p>
</div><p>Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.</p>
<div class="lb-trans"><p>雅培是一家全球醫療保健公司，總部位於伊利諾伊州的雅培公園，開發、製造和銷售廣泛的醫療產品和服務。雅培成立於 1888 年，通過多個業務領域運營，專注於診斷、醫療設備、營養品和成熟藥品。該公司向醫院、診所、實驗室、零售商和直接面向消費者的渠道提供旨在診斷、治療和管理各種健康狀況的產品。</p>
</div><p>In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.</p>
<div class="lb-trans"><p>在診斷方面，雅培提供實驗室和現場檢測平台及用於檢測傳染病、慢性病和生物標誌物的檢測方法；其 Alinity 系列儀器和快速檢測解決方案就是這一能力的例子。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>精選文章</h2>
</div><ul>
<li>Five stocks we like better than Abbott Laboratories</li>
<li>HIVE Weaponizes Power for an AI Pivot</li>
<li>A Deep Dive Into NVIDIA’s Latest Portfolio Moves</li>
<li>Brady Corp Wires Up a Massive AI-Powered Breakout</li>
<li>Why Home Depot’s Sell-Off Could Become a Huge Opportunity</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票超過雅培</li>
<li>HIVE 利用電力進行人工智能轉型</li>
<li>深入探討 NVIDIA 最新的投資組合動態</li>
<li>布雷迪公司推出大規模人工智能驅動的突破</li>
<li>為什麼家得寶的拋售可能成為一個巨大機會</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUFCVA" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NYSE&amp;Symbol=ABT"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。如對本故事有任何問題或意見，請發送電子郵件至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Abbott Laboratories Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1000 美元在雅培嗎？</h2>
</div><p>Before you consider Abbott Laboratories, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮雅培之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Abbott Laboratories wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師正在悄悄建議客户現在購買的股票，以便在更廣泛的市場注意到之前……而雅培並不在名單上。</p>
</div><p>While Abbott Laboratories currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然雅培目前在分析師中獲得了適度買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Harvest Portfolios Group Inc. 增加了其在雅培公司 $ABT 的持股